Evaluation of Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, in Rats With Doxorubicin-Induced Cardiomyopathy: Evidence for Chronic Cardio-Protection.

Youngblood, Brad; Yeh, Steven T; Georgopoulos, Lynne; Arnold, Susan; Wallery, Jeff; Hamlin, Robert L.; Rı́o, Laura Del

doi:10.1016/j.cardfail.2012.06.213

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this, few toxicological studies have been reported to support or refute the potential for these nanomaterials. Although no ELPs are approved for human use, two ELP-containing investigational drugs remain under evaluation for safety and efficacy in clinical trials. , …”

Section: Introductionmentioning

confidence: 99%

“…Although no ELPs are approved for human use, two ELP-containing investigational drugs remain under evaluation for safety and efficacy in clinical trials. 6,26 Our group recently employed ELPs to fabricate nanoparticles that deliver rapamycin (Rapa). 24 Rapa, also called sirolimus, is a potent immunosuppressive approved for the prevention of transplanted rejection.…”

Section: Introductionmentioning

confidence: 99%

“…Elastin-like polypeptides (ELPs) are emerging biomaterials with numerous proposed applications in drug delivery, − tissue engineering, − gene delivery, − and regenerative medicine. , ELPs are protein polymers inspired by hydrophobic peptides within human tropoelastin. The most common ELPs contain pentapeptides, [Val-Pro-Gly-X aa -Gly] n , where X aa can be any amino acid and n specifies the number of repeats.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer

2020

View full text Add to dashboard Cite

The clinical utility of rapamycin (Rapa) is limited by solubility, bioavailability, and side effects. To overcome this, our team recently reported an elastin-like polypeptide (ELP) nanoparticle with high affinity, noncovalent drug binding, and integrin-mediated cellular uptake. Given the scarcity of pharmacology/toxicology studies of ELP-based drug carriers, this article explores safety and efficacy of ELP-Rapa. ELP-Rapa nanoparticles tested negative for hemolysis, did not interfere in plasma coagulation nor in platelet function, and did not activate the complement. Upon incubation with HepG2 cells, ELP-Rapa revealed significant cellular uptake and trafficking to acidic organelles, consistent with lysosomes. Internalized ELP-Rapa nanoparticles increased oxidative stress 4-fold compared to free drug or free ELP controls. However, mice bearing orthotopic hormone receptor positive BT-474 breast tumors, given a high dose (∼10-fold above therapeutic dose) of 1 month administration of ELP-Rapa, did not induce hepatotoxicity. On the other hand, tumor growth and mTOR signaling were suppressed without affecting body weight. Nanoparticles assembled using ELP technology appear to be a safe and efficient strategy for delivering Rapa.

show abstract

Section: Introductionmentioning

confidence: 99%